The estimated Net Worth of Martin Babler is at least $2.57 Million dollars as of 23 June 2020. Mr. Babler owns over 15,000 units of Neoleukin Therapeutics stock worth over $55,177 and over the last 17 years he sold NLTX stock worth over $2,517,615. In addition, he makes $0 as Director at Neoleukin Therapeutics.
Martin has made over 3 trades of the Neoleukin Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of NLTX stock worth $45,000 on 23 June 2020.
The largest trade he's ever made was selling 29,500 units of Neoleukin Therapeutics stock on 17 December 2019 worth over $1,565,565. On average, Martin trades about 3,132 units every 10 days since 2008. As of 23 June 2020 he still owns at least 15,810 units of Neoleukin Therapeutics stock.
You can see the complete history of Mr. Babler stock trades at the bottom of the page.
Martin Babler serves as Director of the Company. Mr. Babler has served as Chief Executive Officer at Principia Biopharma Inc., a biopharmaceutical company. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler was previously employed at Eli Lilly and Company, a pharmaceutical company, in positions focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the board of directors of Principia Biopharma and on the Emerging Companies Section and the Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Martin Babler is 55, he's been the Director of Neoleukin Therapeutics since 2020. There are 4 older and 7 younger executives at Neoleukin Therapeutics. The oldest executive at Neoleukin Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director.
Martin's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over $425,653 worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth $38,477,971 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red..., and Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $593,084. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth $1,462,619.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics executives and other stock owners filed with the SEC include: